| |  Online-Ressource |
|---|
| Verfasst von: | Pixberg, Constantin Frederic [VerfasserIn]  |
|---|
| | Zapatka, Marc [VerfasserIn] |
|---|
| | Hlevnjak, M. [VerfasserIn] |
|---|
| | Benedetto, S. [VerfasserIn] |
|---|
| | Suppelna, J. P. [VerfasserIn] |
|---|
| | Heil, Jörg [VerfasserIn] |
|---|
| | Smetanay, Katharina [VerfasserIn] |
|---|
| | Michel, Laura L. [VerfasserIn] |
|---|
| | Fremd, Carlo [VerfasserIn] |
|---|
| | Körber, V. [VerfasserIn] |
|---|
| | Rübsam, M. [VerfasserIn] |
|---|
| | Buschhorn, Lars [VerfasserIn] |
|---|
| | Heublein, Sabine [VerfasserIn] |
|---|
| | Schäfgen, Benedikt [VerfasserIn] |
|---|
| | Golatta, Michael [VerfasserIn] |
|---|
| | Gomez, C. [VerfasserIn] |
|---|
| | Au, Alexandra von [VerfasserIn] |
|---|
| | Wallwiener, Markus [VerfasserIn] |
|---|
| | Wolf, Sebastian Immanuel [VerfasserIn] |
|---|
| | Dikow, Nicola [VerfasserIn] |
|---|
| | Schaaf, Christian P. [VerfasserIn] |
|---|
| | Gutjahr, Ewgenija [VerfasserIn] |
|---|
| | Allgäuer, Michael [VerfasserIn] |
|---|
| | Stenzinger, Albrecht [VerfasserIn] |
|---|
| | Pfütze, K. [VerfasserIn] |
|---|
| | Kirsten, R. [VerfasserIn] |
|---|
| | Hübschmann, Daniel [VerfasserIn] |
|---|
| | Sinn, Peter [VerfasserIn] |
|---|
| | Jäger, Dirk [VerfasserIn] |
|---|
| | Trumpp, Andreas [VerfasserIn] |
|---|
| | Schlenk, Richard Friedrich [VerfasserIn] |
|---|
| | Höfer, Thomas [VerfasserIn] |
|---|
| | Thewes, V. [VerfasserIn] |
|---|
| | Schneeweiss, Andreas [VerfasserIn] |
|---|
| | Lichter, Peter [VerfasserIn] |
|---|
| Titel: | Cognition |
|---|
| Titelzusatz: | a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy |
|---|
| Verf.angabe: | C. Pixberg, M. Zapatka, M. Hlevnjak, S. Benedetto, J.P. Suppelna, J. Heil, K. Smetanay, L. Michel, C. Fremd, V. Körber, M. Rübsam, L. Buschhorn, S. Heublein, B. Schäfgen, M. Golatta, C. Gomez, A. von Au, M. Wallwiener, S. Wolf, N. Dikow, C. Schaaf, E. Gutjahr, M. Allgäuer, A. Stenzinger, K. Pfütze, R. Kirsten, D. Hübschmann, H.-P. Sinn, D. Jäger, A. Trumpp, R. Schlenk, T. Höfer, V. Thewes, A. Schneeweiss & P. Lichter |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 21 November 2022 |
|---|
| Umfang: | 12 S. |
|---|
| Fussnoten: | Gesehen am 23.01.2023 |
|---|
| Titel Quelle: | Enthalten in: ESMO open |
|---|
| Ort Quelle: | London : BMJ, 2016 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 7(2022), 6, Artikel-ID 100637, Seite 1-12 |
|---|
| ISSN Quelle: | 2059-7029 |
|---|
| Abstract: | Background - COGNITION (Comprehensive assessment of clinical features, genomics and further molecular markers to identify patients with early breast cancer for enrolment on marker driven trials) is a diagnostic registry trial that employs genomic and transcriptomic profiling to identify biomarkers in patients with early breast cancer with a high risk for relapse after standard neoadjuvant chemotherapy (NACT) to guide genomics-driven targeted post-neoadjuvant therapy. - Patients and methods - At National Center for Tumor Diseases Heidelberg patients were biopsied before starting NACT, and for patients with residual tumors after NACT additional biopsy material was collected. Whole-genome/exome and transcriptome sequencing were applied on tumor and corresponding blood samples. - Results - In the pilot phase 255 patients were enrolled, among which 213 were assessable: thereof 48.8% were identified to be at a high risk for relapse following NACT; 86.4% of 81 patients discussed in the molecular tumor board were eligible for a targeted therapy within the interventional multiarm phase II trial COGNITION-GUIDE (Genomics-guided targeted post neoadjuvant therapy in patients with early breast cancer) starting enrolment in Q4/2022. An in-depth longitudinal analysis at baseline and in residual tumor tissue of 16 patients revealed some cases with clonal evolution but largely stable genetic alterations, suggesting restricted selective pressure of broad-acting cytotoxic neoadjuvant chemotherapies. - Conclusions - While most precision oncology initiatives focus on metastatic disease, the presented concept offers the opportunity to empower novel therapy options for patients with high-risk early breast cancer in the post-neoadjuvant setting within a biomarker-driven trial and provides the basis to test the value of precision oncology in a curative setting with the overarching goal to increase cure rates. |
|---|
| DOI: | doi:10.1016/j.esmoop.2022.100637 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.esmoop.2022.100637 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S205970292200271X |
|---|
| | DOI: https://doi.org/10.1016/j.esmoop.2022.100637 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | curative precision oncology |
|---|
| | early breast cancer |
|---|
| | molecularly targeted therapy |
|---|
| | prospective precision oncology trial |
|---|
| | tumor evolution |
|---|
| K10plus-PPN: | 1831785323 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Cognition / Pixberg, Constantin Frederic [VerfasserIn]; 21 November 2022 (Online-Ressource)
